Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies

Trial Profile

Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Futuximab/modotuximab (Primary) ; Capecitabine; Fluorouracil
  • Indications Colorectal cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors EMD Serono; Merck KGaA; Symphogen
  • Most Recent Events

    • 02 Aug 2017 The trial has been completed in Belgium (End Date:13-06-2014)
    • 27 Jul 2017 The trial has been completed in Poland according to European Clinical Trials Database record.
    • 25 Jul 2017 The trial has been completed in Spain according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top